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Background.– TOWER is a prospective, Phase IV, dose titration clinical trial
(NCT01603459) investigating the safety and efficacy of incobotulinumtoxinA
(Xeomin®) in patients with spasticity, deemed to require doses higher than
currently approved.
Methods.– Patients (18–80 years) with upper- and lower-limb spasticity of
the same body side due to cerebral causes, deemed by the investigator to
require total body doses up to 800 U of incobotulinumtoxinA per injection
cycle, will undergo 3 injection cycles (400, 600, and 800 U incobotulinum-
toxinA, respectively), each followed by 12- to 16-week observation periods
with telephone contacts at 1 and 2 weeks and follow-up visits at 4, 8, and
12-16 weeks post-treatment. Co-primary outcome measures are adverse events
and investigator’s global assessment of tolerability. Muscle tone (Ashworth
Scale), Resistance to Passive Movement Scale, Functional Ambulation Clas-
sification scale, Goal Attainment Scale, Disability Assessment Scale, quality
of life, antibody formation, and pulmonary function will also be asses-
sed.
Results.– As of October 2013, patients (enrolment target 150) are being recruited
at 33 sites throughout Europe, Canada and the USA.
Conclusions.– TOWER will provide important insights into the safety and
efficacy of higher than currently recommended incobotulinumtoxinA doses in
patients with multifocal upper- and lower-limb spasticity.
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Background.– Studies have demonstrated reduction of spastic dystonia with
sustained stretch. The aim of the present work was to evaluate the effects
of upper limb wrist-worn loading in a patient with elbow flexor spastic
dystonia.
Methods.– A 53-year old male with left spastic hemiparesis secondary to a
cerebral infarct 2 years prior has benefited from a 3-month rehabilitation pro-
gram, including botulinum toxin injections at the Neurorehabilitation Day
Hospital in Albert-Chenevier hospital, Créteil, France. Within this program
the patient has worn a loaded wrist splint (1.5 kg) daily. Every day, he repor-
ted the total loading time together with any untoward effects in a diary.
Once monthly we monitored spasticity with the Tardieu Scale and active
arm function with the Modified Frenchay Scale using blinded review by two
examiners.
Results.– Maximal range of passive motion against the elbow flexors (XV1)
increased from 144◦ to 164◦ (+20◦), angle of catch (XV3) from 92◦ to 116◦
(+24◦) and active motion range (A) from 78◦ to 92◦ (+14◦). Regarding active
limb function, score improved by 1/10 point for three tasks involving active
elbow extension.
Conclusion.– Upper limb loading may be of benefit in hemiparesis to reduce
elbow flexor spastic dystonia and improve functionality.
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Background.– Type A botulinum toxin has been used in paraspinal muscles
for several conditions like stiff-person syndrome, back pain in cerebral palsy,
chronic low back pain, X-linked dystonia-parkinsonism.
Methods.– A 30-years old woman developed a spastic quadriplegia with right
side more involved, after a severe stroke at the age of 19. Although she was
following a rehabilitation programme for several years, she only improved her
ability to walk slowly for up to 30 steps unaided.
Results.– After treatment with type A botulinum toxin (Botox) for 6 years in limb
muscles, during the last 2 years, she developed a scoliosis which interfered with
her gait pattern. Right paraspinal thoracic muscles were injected, with botulinum
toxin in 6 segments, using 20 U in each site. This treatment was repeated 4 times
each year. Patient improved posture in standing position and facilitated the gait
pattern and velocity. She could walk more than 50 steps without assistance,
without body shifting and with a faster gait speed.
Conclusions.– Administration of botulinum toxin A reduced the tone of para-
spinal and improves significantly improvement of gait pattern in quadriplegic
woman.
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Background.– Intrathecal baclofen has been used to treat lower limb spasticity
in hereditary spastic paraparesis. Botulinum toxin type A has also been used for
the same reason.
Methods.– We present three cases of women (aged 47, 58, and 59) with hereditary
spastic paraparesis treated in our PRM department.
Results.– Patients were under intramuscular antispastic treatment with 400 U of
type A botulinum toxin for two years period, in hip adductors, hamstrings and
triceps surae. After 4, 8, 12, 16, 20 and 24 months of botulinum toxin, Modi-
fied Ashworth Scale showed improvement of spasticity not enough to improve
the gait velocity, measured with 10 m walking test. Patients were referred to
Neurosurgical department where they were treated with permanent intrathecal
baclofen pump, after positive test of 50g baclofen intrathecally. MAS score
was also improved but with not significant improvement in gait pattern. Daily
living activities were improved.
Conclusions.– Both botulinum toxin and intrathecal baclofen can reduce spas-
ticity in hereditary spastic paraparesis. Walking ability of these persons is still a
big question depending on the degree of paralysis and the severity of the disease.
http://dx.doi.org/10.1016/j.rehab.2014.03.177
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